Jennifer L. McQuade - Concepedia

Author

Jennifer L. McQuade

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

J McQuade, J. Mcquade, J.L. McQuade, Jennifer L McQuade, Jennifer L. McQuade, Jennifer Leigh McQuade, Jennifer McQuade, Jennifer Mcquade, Jim McQuade, Shaneen Sandhu

354

Publications

11.4K

Citations

H-Index

108

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Melanoma Institute Australia Memorial Sloan Kettering Cancer Center The University of Sydney Royal North Shore Hospital

About

Jennifer L. McQuade is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, radiation oncology, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	30	4K
2	Health Sciences	7	7	843
3	Education	2	2	104
4	Arts	1	1	23
5	Nursing	1	1	18

Jennifer L. McQuade

Publications

8.8K

Citations

H-Index

Page 1

	Year	Citations
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy Weiyi Peng, Jie Qing Chen, Chengwen Liu, Cancer Discovery	2015	1.5K
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab Alexander M. Menzies, Douglas B. Johnson, Sangeetha Ramanujam, Annals of Oncology Autoimmune DisordersAutoimmune DiseaseAnti-pd-1 TherapyMelanomaImmunology	2016	811
Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response Christine N. Spencer, Jennifer L. McQuade, Vancheswaran Gopalakrishnan, Science NutritionDysbiosisGut BacteriaImmunologyDietary Fibre	2021	804
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis Jennifer L. McQuade, Carrie R. Daniel, Kenneth R. Hess, The Lancet Oncology OncologyBody CompositionCancer ManagementMelanomaMetastatic Melanoma	2018	647
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade Miles C. Andrews, Connie P.M. Duong, Vancheswaran Gopalakrishnan, Nature Medicine DysbiosisHealth SciencesMucosal ImmunologyPd-1 BlockadeMedicine	2021	388
Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations Curtis H. Kugel, Stephen M. Douglass, Marie R. Webster, Clinical Cancer Research	2018	347
Molecular Profiling Reveals Unique Immune and Metabolic Features of Melanoma Brain Metastases Grant M. Fischer, Ali Jalali, David A. Kircher, Cancer Discovery	2019	334
Neoadjuvant relatlimab and nivolumab in resectable melanoma Rodabe N. Amaria, Michael A. Postow, Elizabeth M. Burton, Nature	2022	312
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial Rodabe N. Amaria, Peter A. Prieto, Michael T. Tetzlaff, The Lancet Oncology Surgical OncologyMedicineCancer ManagementMelanomaClinical Trials	2018	285
Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma C. Owen, Xue Bai, Serigne Lo, Annals of Oncology Tumor ImmunologyMelanomaImmunologyImmune Checkpoint InhibitorAutoimmunity	2021	172

Page 1